〔Abstract〕 Objective To study the application value of paclitaxel combined with nedaplatin intraperitoneal hyperthermic perfusion in the treatment of digestive tract malignant tumor. Methods 62 patients with digestive tract malignant tumor admitted to Ruichang People's Hospital from April 2015 to April 2021 were divided into hot perfusion group and intravenous administration group, with 31 cases in each group. Both groups were given paclitaxel combined with nedaplatin. The hot perfusion group used intraperitoneal hot perfusion to complete chemotherapy, while the intravenous administration group used intravenous drip to complete chemotherapy. The curative effect of tumor between the two groups was compared, The levels of tumor markers [carbohydrate antigen 19–9 (CA19–9), carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE)] were compared before and after treatment, and the patients' nausea, alopecia, neurotoxicity, liver and kidney injury, bone marrow suppression and so on were recorded and compared. Results The objective remission rate (ORR) of patients in the hot perfusion group was 83.87%, which was higher than 61.29% in the intravenous administration group, and the difference were statistically significant (P < 0.05). After treatment, CA19–9, CEA and NSE of patients in the two groups all decreased in different degrees, these indexes in the hot perfusion group were lower than those in the intravenous administration group and the differences were statistically significant (P < 0.05). The incidence of adverse reactions in hot perfusion group was 51.61%, which was not statistically significant compared with 64.51% in intravenous administration group (P > 0.05). Conclusion Paclitaxel combined with nedaplatin intraperitoneal hyperthermic perfusion is of high value in the treatment of digestive tract malignant tumors.